EUCTR2011-000053-23-DE进行中（未招募）不适用
Multicenter, double-blind, placebo-controlled, two-arm, randomized, parallel, treatment intervention, sleep lab phase 4 study to assess the effect of rotigotine on nocturnal blood pressure in patients with idiopathic restless legs syndrome - ENCORE
CB Biosciences GmbH0 个研究点开始时间: 2011年5月13日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is informed and given ample time and opportunity to think about her/his participation and give her/his written informed consent.
- •2. Subject understands the investigational nature of the study and is willing and able to comply with the study requirements. Subject is willing to accept that he/she might be treated with placebo during the Treatment Period.
- •3. Subject is able to apply/remove the study patch correctly.
- •4. Subject is male or female, and is =18 and =75 years of age.
- •5. Subject meets the diagnosis of idiopathic RLS based on the 4 essential clinical features according to the International Restless Legs Syndrome Study Group (Allen et al, 2003):
- •a. An urge to move legs, usually accompanied or caused by
- •uncomfortable and unpleasant sensations in the legs.
- •(The urge to move can be present without uncomfortable
- •sensations. Arms or other body parts can also be affected.)
- •b. The urge to move or unpleasant sensations begin or worsen
- •during periods of rest or inactivity, such as lying or sitting.
- •c. The urge to move or unpleasant sensations are partially or totally
- •relieved by movement, such as walking or stretching, at least as
- •long as the activity continues.
- •d. The urge to move or unpleasant sensations are worse in the
- •evening or night than during the day or only occur in the evening
- •or night. (When symptoms are very severe, the worsening at
- •night may not be noticeable but must have been previously
- •6. Subject has a score of =11 on the RLS-Diagnostic Index (RLS-DI) (Benes and Kohnen, 2009).
- •7. Subject has an initial response to previous dopaminergic treatment for RLS or has no previous dopaminergic treatment (ie, de novo).
- •8. The subject’s body mass index (BMI) is =18kg/m2 and =35kg/m2.
- •9. At Baseline (Visit 2), subject has a score of =15 on the IRLS (indicating moderate to severe RLS).
- •10. At Baseline (Visit 2), subject has a score of =4 points on the CGI Item 1 assessment (indicating moderately ill).
- •11. At Baseline (Visit 2), subject has a score of =15 PLM/h on the PLMI based on polysomnography (PSG) (recorded during the second night) as assessed by the investigator.
- •12. Subjects are on a concomitant dose of antihypertensives that is at a stable dose for at least 4 weeks prior to Baseline (Visit 2) and
- •hypertension is reasonably controlled while the subject agrees to continue at this dose for the duration of the study, or subject has not
- •received concomitant treatment with antihypertensives for at least 4 weeks prior to Baseline (Visit 2) and does not intend to start such use during the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 47
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •1. Subject has RLS due to renal insufficiency (uremia), iron deficiency anemia, or rheumatoid arthritis.
- •2. Subject has RLS associated with previous or concomitant therapy with dopamine D2 receptor antagonists, butyrophenones, metoclopramide, atypical antipsychotics (eg, olanzapine), tri- and tetra-cyclic antidepressants, mianserine, or lithium or H2-blockers (eg, cimetidine), or due to withdrawal from drugs such as anticonvulsants,
- •benzodiazepines, barbiturates, and other hypnotics.
- •3. Subject has a history of sleep disturbances, such as sleep apnea syndrome (including obstructive sleep apnea), narcolepsy, sleep attacks/sudden onset of sleep, or myoclonus epilepsy either observed during PSG (local PSG evaluations) or evidenced by subject history.
- •4. Subject has uncontrolled hypertension according to the judgment of the investigator.
- •5. Subject has additional clinically relevant concomitant diseases, such as attention deficit hyperactivity disorder, polyneuropathy, akathisia, claudication, varicosis, muscle fasciculation, painful legs and moving toes, or radiculopathy.
- •6. Subject has other central nervous system diseases, such as Parkinson’s disease, dementia, progressive supranuclear paresis, multisystem atrophy, Huntington’s chorea, amyotrophic
- •lateral sclerosis, or Alzheimer’s disease.
- •7. Subject has a prior history of psychotic episodes.
- •8. Subject has a history of chronic alcohol or drug abuse within the previous 12 months.
- •9. Subject has any medical or psychiatric condition, which in the opinion of the investigator, can jeopardize or would compromise the subject’s ability to participate in this study.
- •10. Subject has clinically relevant cardiac dysfunction and/or arrhythmias (eg, suspected conduction system dysregulations, second or third degree atrioventricular block, complete left or right bundle branch block, sick sinus syndrome, New York Heart Association Class III or IV congestive heart failure, or had a myocardial infarction within
- •12 months prior to Screening [Visit 1]).
- •11. Subject has clinically relevant venous or arterial peripheral vascular disease.
- •12. Subject has a malignant neoplastic disease requiring therapy within 12 months prior to Screening (Visit 1).
- •13. Subject is currently receiving treatment with any of the following drug classes: neuroleptics, hypnotics, antidepressants, anxiolytic drugs, anticonvulsive therapy, budipine, dopamine antagonist antiemetics (except domperidone), opioids, benzodiazepines, monoamine oxidase (MAO) inhibitors, catechol-O-methyltransferase
- •(COMT) inhibitors, sedative antihistamines, psychostimulates, or amphetamines. If subject has received such therapy, a Washout Period of at least 7 days prior to Baseline (Visit 2) is required before starting treatment in this study.
- •14. Subject is pregnant, nursing, or is a woman of childbearing potential who is not surgically sterile, 2 years postmenopausal, or does not consistently use 2 combined effective methods of contraception, including at least 1 barrier method, unless sexually abstinent.
- •15. Subject is a shift worker or performs other continuous non–disease-related life conditions which do not allow regular sleep at night.
- •16. At Screening Visit (Visit 1) or Baseline Visit (Visit 2), subject has symptomatic orthostatic hypotension with a decrease of BP from supine to standing position of =20mmHg in systolic BP or of =10mmHg in diastolic BP taken from the 5-minute supine
- •and 1- and/or 3-m
研究者
相似试验
进行中（未招募）
不适用
Multi-center, double-blind, placebo-controlled, four-arm, randomized phase II dose finding study with Sokatin® (WS® 1261) in patients with a Major Depressive EpisodeEUCTR2006-001756-13-DEDr. Willmar Schwabe GmbH & Co. KG400
进行中（未招募）
不适用
Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Studyto Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the AcuteTreatment of Migraine With or Without Aura.Patient has had a history of migraine with or without aura > 1 year with 𕟳 and 𕟰 moderate or severe migraine attacks per month in the 2 months prior to screening that typically last between 4 to 72 hours untreatedMedDRA version: 14.1Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2007-002667-28-ITMERCK & CO., INC.1,800
已完成
3 期
Multicenter double-blind, randomized, placebo-controlled trial of IDEC-C2B8 for the treatment of childhood-onset nephrotic syndrome(JSKDC10)Childhood onset idiopathic nephrotic syndrome showing frequent relapse or steroid dependenceJPRN-jRCT1091220380Kobe University Hospital40
进行中（未招募）
1 期
Study to assess the efficacy and safety of ACT-541468 in adult subjects suffering from difficulties to sleepEUCTR2016-000826-21-SEActelion Pharmaceuticals Ltd300
进行中（未招募）
1 期
A study to test whether spesolimab helps people with Crohn's disease whohave symptoms of bowel obstructioEUCTR2020-005770-99-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.100